Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Topical ABI-1968 in Subjects With Anal High-Grade Squamous Intraepithelial Lesions (aHSIL)

NCT03202992 is registered in ClinicalTrials.gov with Antiva Biosciences as lead sponsor.

NCT NCT03202992
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03202992 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Topical ABI-1968 in Subjects With Anal High-Grade Squamous Intraepithelial Lesions (aHSIL)
Lead sponsor
Antiva Biosciences
Phase
Phase 1
Overall status
Completed
Start date
August 11, 2017
Completion date
February 4, 2019
Enrollment
57 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

anal cancer, anus neoplasms, hiv infection, hsil, high-grade squamous intraepithelial lesions, human papilloma virus infection